Methods for direct fluorescent antibody virus detection in liquids
View Patent ↗The present invention describes a liquid direct fluorescence antibody assay that is rapid and sensitive to detect respiratory virus in infected cells. The assay includes centrifugation of the specimen, incubation of sample and reagents in solution, and detection of the absence or presence of respiratory virus. Sapogenin is used as a detergent to permeabilize the cells for entry of the monoclonal antibodies to react with intracellular antigens. The cells are stained with fluorescently labeled monoclonal antibodies against the viral antigens along with a background stain and a fluorescent nuclear stain. This counter staining decreases background and allows co-localization of antigen and nuclear structures for enhanced detection.
1. A method, comprising;
a) providing;
i)a suspension comprising a biological sample, wherein said sample is suspected of comprising at least two viral antigens, wherein said suspension further comprises a staining reagent selected from the group consisting of Evans blue, propidium iodide, acridine orange and combinations thereof;
iii) at least two fluorescently labeled antibodies, wherein each of said at least two viral antigens is capable of directly binding to one of said at least two said fluorescently labeled antibodies, wherein said antibodies are differently labeled;
b) incubating said suspension with said fluorescently labeled antibodies under conditions such that each of said fluorescently labeled antibodies directly binds one of said viral antigens, thereby forming at least one labeled antigen-antibody complex; and
c) detecting said at least one labeled antigen-labeled antibody complex within said suspension by identifying at least one fluorescently labeled antibody, thereby identifying at least one of said at least two viral antigens.
2. The method of claim 1 , wherein said fluorescently labeled antibodies comprise monoclonal antibodies.
3. The method of claim 1 , wherein said viral antigen comprises a respiratory syncytial viral antigen.
4. The method of claim 2 , wherein at least one of said fluorescently labeled monoclonal antibodies comprise specific affinity for said respiratory syncytial viral antigen.
5. The method of claim 4 , wherein said fluorescently labeled monoclonal respiratory syncytial virus antibody comprises a R-phycoerythrin fluorescent label.
6. The method of claim 1 , wherein said viral antigen comprises an influenza viral antigen.
7. The method of claim 6 , wherein said influenza viral antigen comprises an influenza A viral antigen.
8. The method of claim 6 , wherein said influenza viral antigen comprises an influenza B viral antigen.
9. The method of claim 2 , wherein at least one of said fluorescently labeled monoclonal antibodies comprise a specific affinity for said influenza A viral antigen.
10. The method of claim 7 , wherein said fluorescently labeled influenza A monoclonal antibody comprises a R-phycoerythrin fluorescent label.
11. The method of claim 2 , wherein at least one of said fluorescently labeled monoclonal antibodies comprise a specific affinity for said influenza B viral antigen.
12. The method of claim 11 , wherein said fluorescently labeled influenza B monoclonal antibody comprises a fluorescein isothiocyanate fluorescent label.
13. The method of claim 1 , wherein said viral antigen comprises an adenovirus viral antigen.
14. The method of claim 2 , wherein at least one of said fluorescently labeled monoclonal antibodies comprise a specific affinity for said adenovirus viral antigen.
15. The method of claim 14 , wherein said fluorescently labeled adenovirus monoclonal antibody comprises a fluorescein isothiocyanate fluorescent label.
16. The method of claim 1 , wherein said viral antigen comprises a parainfluenza viral antigen.
17. The method of claim 16 , wherein said parainfluenza viral antigen comprises a parainfluenza 1 viral antigen.
18. The method of claim 16 , wherein said parainfluenza viral antigen comprises a parainfluenza 2 viral antigen.
19. The method of claim 16 , wherein said parainfluenza viral antigen comprises a parainfluenza 3 viral antigen.
20. The method of claim 2 , wherein at least one of said fluorescently labeled monoclonal antibodies comprise a specific affinity for said parainfluenza viral antigen.
21. The method of claim 20 , wherein said fluorescently labeled parainfluenza monoclonal antibody comprises a R-phycoerythrin fluorescent label.
22. The method of claim 21 , wherein said fluorescently labeled parainfluenza monoclonal antibody comprises a specific affinity for said parainfluenza 1 viral antigen.
23. The method of claim 21 , wherein said fluorescently labeled parainfluenza monoclonal antibody comprises a specific affinity for said parainfluenza 2 viral antigen.
24. The method of claim 21 , wherein said fluorescently labeled parainfluenza monoclonal antibody comprises a specific affinity for said parainfluenza 3 viral antigen.
25. The method of claim 1 , wherein said viral antigen comprises a metapneumovirus viral antigen.
26. The method of claim 2 , wherein said fluorescently labeled monoclonal antibody comprises a specific affinity for said metapneumovirus viral antigen.
27. The method of claim 26 , wherein said fluorescently labeled metapneumovirus monoclonal antibody comprises a fluorescein isothiocyanate fluorescent label.
28. A method, comprising;
a) providing;
i) a suspension comprising a biological sample, wherein said sample is suspected of comprising at least two viral antigens, wherein said suspension further comprises a detergent;
iii) at least two fluorescently labeled antibodies, wherein each of said at least two viral antigens is capable of directly binding to one of said at least two said fluorescently labeled antibodies, wherein said antibodies are differentially labeled;
b) incubating said suspension with said fluorescently labeled antibodies under conditions such that each of said fluorescently labeled antibodies directly binds one of said viral antigens, thereby forming at least one labeled antigen-antibody complex; and
c) detecting said at least one labeled antigen-labeled antibody complex within said suspension by identifying at least one fluorescently labeled antibody, thereby identifying at least one of said at least two viral antigens.
29. A method, comprising;
a) providing;
i) a suspension comprising a biological sample, wherein said sample is suspected of comprising at least two viral antigens, wherein said detergent is sapogenin;
iii) at least two fluorescently labeled antibodies, wherein each of said at least two viral antigens is capable of directly binding to one of said at least two said fluorescently labeled antibodies, wherein said antibodies are differentially labeled;
b) incubating said suspension with said fluorescently labeled antibodies under conditions such that each of said fluorescently labeled antibodies directly binds one of said viral antigens, thereby forming at least one labeled antigen-antibody complex; and
c) detecting said at least one labeled antigen-labeled antibody complex within said suspension by identifying at least one fluorescently labeled antibody, thereby identifying at least one of said at least two viral antigens.
30. The method of claim 28 , wherein said fluorescently labeled antibodies comprise monoclonal antibodies.
31. The method of claim 28 , wherein said viral antigen comprises a respiratory syncytial viral antigen.
32. The method of claim 30 , wherein at least one of said fluorescently labeled monoclonal antibodies comprise specific affinity for said respiratory syncytial viral antigen.
33. The method of claim 32 , wherein said fluorescently labeled monoclonal respiratory syncytial virus antibody comprises a R-phycoerythrin fluorescent label.
34. The method of claim 28 , wherein said viral antigen comprises an influenza viral antigen.
35. The method of claim 34 , wherein said influenza viral antigen comprises an influenza A viral antigen.
36. The method of claim 34 , wherein said influenza viral antigen comprises an influenza B viral antigen.
37. The method of claim 30 , wherein at least one of said fluorescently labeled monoclonal antibodies comprise a specific affinity for said influenza A viral antigen.
38. The method of claim 35 , wherein said fluorescently labeled influenza A monoclonal antibody comprises a R-phycoerythrin fluorescent label.
39. The method of claim 30 , wherein at least one of said fluorescently labeled monoclonal antibodies comprise a specific affinity for said influenza B viral antigen.
40. The method of claim 39 , wherein said fluorescently labeled influenza B monoclonal antibody comprises a fluorescein isothiocyanate fluorescent label.
41. The method of claim 28 , wherein said viral antigen comprises an adenovirus viral antigen.
42. The method of claim 30 , wherein at least one of said fluorescently labeled monoclonal antibodies comprise a specific affinity for said adenovirus viral antigen.
43. The method of claim 42 , wherein said fluorescently labeled adenovirus monoclonal antibody comprises a fluorescein isothiocyanate fluorescent label.
44. The method of claim 28 , wherein said viral antigen comprises a parainfluenza viral antigen.
45. The method of claim 44 , wherein said parainfluenza viral antigen comprises a parainfluenza 1 viral antigen.
46. The method of claim 44 , wherein said parainfluenza viral antigen comprises a parainfluenza 2 viral antigen.
47. The method of claim 44 , wherein said parainfluenza viral antigen comprises a parainfluenza 3 viral antigen.
48. The method of claim 30 , wherein at least one of said fluorescently labeled monoclonal antibodies comprise a specific affinity for said parainfluenza viral antigen.
49. The method of claim 48 , wherein said fluorescently labeled parainfluenza monoclonal antibody comprises a R-phycoerythrin fluorescent label.
50. The method of claim 49 , wherein said fluorescently labeled parainfluenza monoclonal antibody comprises a specific affinity for said parainfluenza 1 viral antigen.
51. The method of claim 49 , wherein said fluorescently labeled parainfluenza monoclonal antibody comprises a specific affinity for said parainfluenza 2 viral antigen.
52. The method of claim 49 , wherein said fluorescently labeled parainfluenza monoclonal antibody comprises a specific affinity for said parainfluenza 3 viral antigen.
53. The method of claim 28 , wherein said viral antigen comprises a metapneumovirus viral antigen.
54. The method of claim 30 , wherein said fluorescently labeled monoclonal antibody comprises a specific affinity for said metapneumovirus viral antigen.
55. The method of claim 54 , wherein said fluorescently labeled metapneumovirus monoclonal antibody comprises a fluorescein isothiocyanate fluorescent label.
56. The method of claim 29 , wherein said fluorescently labeled antibodies comprise monoclonal antibodies.
57. The method of claim 29 , wherein said viral antigen comprises a respiratory syncytial viral antigen.
58. The method of claim 56 , wherein at least one of said fluorescently labeled monoclonal antibodies comprise specific affinity for said respiratory syncytial viral antigen.
59. The method of claim 58 , wherein said fluorescently labeled monoclonal respiratory syncytial virus antibody comprises a R-phycoerythrin fluorescent label.
60. The method of claim 29 , wherein said viral antigen comprises an influenza viral antigen.
61. The method of claim 60 , wherein said influenza viral antigen comprises an influenza A viral antigen.
62. The method of claim 60 , wherein said influenza viral antigen comprises an influenza B viral antigen.
63. The method of claim 56 , wherein at least one of said fluorescently labeled monoclonal antibodies comprise a specific affinity for said influenza A viral antigen.
64. The method of claim 61 , wherein said fluorescently labeled influenza A monoclonal antibody comprises a R-phycoerythrin fluorescent label.
65. The method of claim 56 , wherein at least one of said fluorescently labeled monoclonal antibodies comprise a specific affinity for said influenza B viral antigen.
66. The method of claim 65 , wherein said fluorescently labeled influenza B monoclonal antibody comprises a fluorescein isothiocyanate fluorescent label.
67. The method of claim 29 , wherein said viral antigen comprises an adenovirus viral antigen.
68. The method of claim 56 , wherein at least one of said fluorescently labeled monoclonal antibodies comprise a specific affinity for said adenovirus viral antigen.
69. The method of claim 68 , wherein said fluorescently labeled adenovirus monoclonal antibody comprises a fluorescein isothiocyanate fluorescent label.
70. The method of claim 29 , wherein said viral antigen comprises a parainfluenza viral antigen.
71. The method of claim 70 , wherein said parainfluenza viral antigen comprises a parainfluenza 1 viral antigen.
72. The method of claim 70 , wherein said parainfluenza viral antigen comprises a parainfluenza 2 viral antigen.
73. The method of claim 70 , wherein said parainfluenza viral antigen comprises a parainfluenza 3 viral antigen.
74. The method of claim 56 , wherein at least one of said fluorescently labeled monoclonal antibodies comprise a specific affinity for said parainfluenza viral antigen.
75. The method of claim 74 , wherein said fluorescently labeled parainfluenza monoclonal antibody comprises a R-phycoerythrin fluorescent label.
76. The method of claim 75 , wherein said fluorescently labeled parainfluenza monoclonal antibody comprises a specific affinity for said parainfluenza 1 viral antigen.
77. The method of claim 75 , wherein said fluorescently labeled parainfluenza monoclonal antibody comprises a specific affinity for said parainfluenza 2 viral antigen.
78. The method of claim 75 , wherein said fluorescently labeled parainfluenza monoclonal antibody comprises a specific affinity for said parainfluenza 3 viral antigen.
79. The method of claim 29 , wherein said viral antigen comprises a metapneumovirus viral antigen.
80. The method of claim 56 , wherein said fluorescently labeled monoclonal antibody comprises a specific affinity for said metapneumovirus viral antigen.
81. The method of claim 80 , wherein said fluorescently labeled metapneumovirus monoclonal antibody comprises a fluorescein isothiocyanate fluorescent label.